

**IN THE CLAIMS**

1. **(Original)** An isolated, purified or recombinant complex comprising a POSH polypeptide and a POSH-associated protein (POSH-AP).
2. **(Original)** The complex of claim 1, wherein the POSH-AP comprises a polypeptide selected from the group consisting of: PKA, SNX1, SNX3, ATP6V0C, PTPN12, PPP1CA, GOSR2, CENTB1, DDEF1, ARF1, ARF5, PACS-1, EPS8L2, HERPUD1, UNC84B, MSTP028, GOCAP, EIF3S3, SRA1, CBL-B, RALA, SIAH1, SMN1, SMN2, SYNE1, TTC3, VCY2IP1 and UBE2N (UBC13).
3. **(Cancelled)**
4. **(Currently Amended)** The complex of claim 1 ~~any one of claims 1-3~~, wherein the POSH polypeptide is a human POSH polypeptide.
- 5-6. **(Cancelled)**
7. **(Currently Amended)** A method for identifying an agent that modulates an activity of a POSH polypeptide or POSH-AP, the method comprising identifying an agent that disrupts a complex of claim 1 ~~any one of claims 1-3~~, wherein an agent that disrupts a complex claim 1 ~~of any of claims 1-3~~ is an agent that modulates an activity of the POSH polypeptide or the POSH-AP.
8. **(Currently Amended)** ~~A method of identifying an antiviral agent. The method of~~ claim 7, further comprising:
  - ~~(a) identifying a test agent that disrupts a complex comprising a POSH polypeptide and a POSH-AP; and~~
  - ~~(b) evaluating the effect of the test agent on a function of a virus,~~wherein an agent that inhibits a pro-infective or pro-replicative function of a virus is an antiviral agent.
9. **(Original)** The method of claim 8, wherein the POSH-AP is selected from the group consisting of: PKA, SNX1, SNX3, PTPN12, GOSR2, CENTB1, ARF1, ARF5,

PACS-1, EPS8L2, HERPUD1, SMN1, SMN2, UNC84B, MSTP028, GOCAP, CBL-B, SYNE1, UBE2N (UBC13), SIAH1, TTC3, WASF1, HIP55, RALA, and SPG20.

10. **(Original)** The method of claim 8, wherein the virus is an envelope virus.
11. **(Original)** The method of claim 8, wherein the virus is a Human Immunodeficiency Virus.
12. **(Cancelled)**
13. **(Cancelled)**
14. **(Original)** The method of claim 8, wherein evaluating the effect of the test agent on a function of the virus comprises evaluating the effect of the test agent on the budding or release of the virus or a virus-like particle.
- 15-23. **(Cancelled)**
24. **(Original)** A method of identifying an agent that inhibits the progression of a neurological disorder, comprising:
  - (a) identifying a test agent that disrupts a complex comprising a POSH polypeptide and a POSH-AP; and
  - (b) evaluating the effect of the test agent on the trafficking of a protein through the secretory pathwaywherein an agent that disrupts localization of a POSH-AP is an agent that inhibits progression of a neurological disorder.
25. **(Original)** The method of claim 24, wherein the POSH-AP is selected from the group consisting of: HERPUD1, CBL-B, SIAH1, and TTC3.
26. **(Original)** The method of claim 25, wherein the POSH-AP is HERPUD1.
- 27-62. **(Cancelled)**

63. **(Original)** A method of identifying an agent that modulates a POSH function, comprising:
- a) identifying an agent that modulates a POSH-AP; and
  - b) testing the effect of the agent on a POSH function.
64. **(Cancelled)**
65. **(Currently Amended)** The method of claim ~~6364~~ ~~or 65~~, wherein the POSH-AP comprises a polypeptide selected from the group consisting of: PKA, SNX1, SNX3, ATP6V0C, PTPN12, PPP1CA, GOSR2, CENTB1, DDEF1, ARF1, ARF5, PACS-1, EPS8L2, HERPUD1, UNC84B, MSTP028, GOCAP, EIF3S3, SRA1, CBL-B, RALA, SIAH1, SMN1, SMN2, SYNE1, TTC3, VCY2IP1 and UBE2N (UBC13).
66. **(Cancelled)**
67. **(Currently Amended)** The method of claim ~~6364~~ ~~or 65~~, wherein testing the effect of the agent on a POSH function comprises testing the effect of the agent on the production of viral particles or virus like particles in a cell infected with an envelope virus.
68. **(Currently Amended)** The method of claim ~~6364~~ ~~or 65~~, wherein testing the effect of the agent on a POSH function comprises testing the effect of the agent on a POSH enzymatic activity.
69. **(Original)** The method of claim 68, wherein the POSH enzymatic activity is ubiquitin ligase activity.
70. **(Currently Amended)** The method of claim ~~6364~~ ~~or 65~~, wherein testing the effect of the agent on a POSH function comprises testing the effect of the agent on POSH-mediated localization or secretion of a protein.
71. **(Currently Amended)** The method of claim ~~6364~~ ~~or 65~~, wherein testing the effect of the agent on a POSH function comprises testing the effect of the agent on the interaction of POSH with a POSH-AP.

72. (Cancelled)

73. (Cancelled)

74. (Currently Amended) The method of claim ~~6364 or 65~~, wherein the test agent is selected from among: an antisense nucleic acid, an siRNA construct, a small molecule, an antibody and a polypeptide.

75-108.(Cancelled)